NEW YORK--(BUSINESS WIRE)--DellaCamera Capital Management, LLC (“DellaCamera”) and related entities, which beneficially hold approximately 8.3% of the shares of Enzon Pharmaceuticals, Inc. (“Enzon” or the “Company”) (NASDAQ: ENZN), today reported on its recent Town Hall Meeting and provided an update to all Enzon shareholders on the consent solicitation process to remove Enzon CEO and President Jeffrey H. Buchalter.
